THC Global's Australian not only signed product distribution agreements with German pharmaceutical importer ACA Muller but also signed agreements with distributors providing services in pharmacies across the EU.
THC Global's Australian plans to provide marijuana drugs starting on the 20th of next month. The medicinal cannabis comes from the Australian cannabis plant material produced by the Southport pharmaceuticals GMP facility.
CEO Ken Charteris explained: "We will be able to offer our Australian produced, high-quality medicinal cannabis medicines under the Canndeo brand for a prescription to Australian patients."
"These medicines will be more affordable and accessible than current products available in Australia, ensuring that more Australian patients in need of these medicines can access them safely through legal access pathways and with the right medical support and supervision".
CanndeoCare, THC's professional team, will provide hospitals with prescriptions for medical cannabis drugs; provide expert opinions on the regulatory process, technical and medical aspects of cannabis drug patient management; and training on medicine selection and medical options.
THC Global's Australian will provide drugs directly to pharmacies, clinics, and hospitals in accordance with the Australian government's supply demands for medical marijuana. It will also provide services to patients under the legal medical marijuana provisions.
Product Distribution in Europe
THC and ACA Muller signed a product distribution agreement. ACA Muller, a German pharmaceutical importer and a distributor of the wholly-owned subsidiary of Franchise Cannabis Corp. It holds the first cannabis license issued by Germany and serves more than 1,200 pharmacies across the European Union.
The product distribution agreement stipulates that ACA Muller will sell medical marijuana across Europe and is expected to start selling in September after obtaining regulatory approval.
Clifford Starke, CEO of Franchise Cannabis Corp, said, "This is a strategic milestone for the company to date which will allow us to diversify our product base into high-quality oils and position us to continue being a leader in Germany and the rest of Europe. Now that THC Global has achieved GMP certification, we are excited to launch a new, distinctive line of medical cannabis-derived extract products. We look forward to working with the THC Global team on many initiatives providing patient access to high-quality products."
This European distribution agreement adds to THC Global ’s existing medical marijuana sales channels, which previously provided these products to Canada and New Zealand.
This article is issued by Proactiveinvestors, Jessica Cummins. For further information, please check out Proctiveinvestors.